Progenity Inc. (PROG) stock surges during current market trading. Here’s to know why?

Progenity Inc. (NASDAQ: PROG) stock gains by 19.67% in the current market trading session. Progenity is a biotechnology firm that develops products for women’s health, gastrointestinal health, and oral biotherapeutics.

>> 7 Top Picks for the Post-Pandemic Economy << 

PROG stock’ Significant Development

The United States Patent and Trademark Office (USPTO) has granted Progenity U.S. Patent No. 11,112,403 for tests for free and dissociated placental growth factor in the diagnosis of preeclampsia. Techniques, formulations, and equipment for identifying and assessing free and dissociated placental growth factor (PlGF) levels in biological samples are covered by the patent. PlGF is a well-known biomarker for the diagnosis of preeclampsia, and new research has demonstrated the necessity of differentiating between the free and bound versions when examining the complicated physiological pathways involved in the disease.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Read More

The Preecludia test is planned to address a $3 billion annual addressable market in the United States. This test has the ability to be used worldwide as an in vitro diagnostic (IVD) and point-of-care solution. Progenity is considering commercialization prospects for the LDT launch in the United States, as well as IVD embodiments to tap the global opportunity for the Preecludia test, in line with the company’s recent strategic shift. The business earlier declared that the clinical validation study had been completed successfully and that the primary study endpoint had been met, and that the study results would be published in a peer-reviewed medical journal.

Furthermore,

Preeclampsia is the second leading cause of maternal death, with over 700,000 pregnant women experiencing indications of preeclampsia each year. Preeclampsia can lead to compromised organ function, seizures, stroke, and death in the mother, as well as pre-term delivery of the baby if left undetected and poorly managed. Preeclampsia can have a negative impact on one’s health as well as cost a lot of money. Because the signs are common happening in up to 30% of pregnant women in the United States and can easily be attributed to other reasons, preeclampsia is frequently missed or misidentified.

Most Popular

Related posts